GlobeNewswire

Presagis Releases New Versions of its Products VAPS XT 4.2, UA Accelerator 3.0, and UA Emulator 3.0

Dela

These new versions strengthen its suite of proven software solutions for developing certifiable graphical user interfaces.

MONTREAL, June 04, 2018 (GLOBE NEWSWIRE) -- Presagis, a leading provider of modeling, simulation, and user interface development software, today announced the release of new versions of its software:

These new versions further enhance an open and extensible COTS graphical HMI modeling and development software suite of solutions for developing real-time applications supporting standard and ARINC 661 certifiable and non-certifiable safety-critical environments. Presagis has provided HMI graphical modeling and development tools to produce state-of-the-art graphics and highly optimized code for both PC and embedded systems for over 30 years.

Presagis' VAPS XT is an easy-to-use yet powerful full-featured software tool for the rapid development of interactive graphical HMI displays for avionics and other applications. It allows a user to capture the design of an HMI, automatically generate source code to implement that design, and ultimately achieve certification to the highest levels of DO-178C. UA Accelerator and UA Emulator complement VAPS XT when designing an ARINC 661 System, linking graphics layout development with development of the UA system model and providing analysis of ARINC 661 Protocol.

VAPS XT 4.2

VAPS XT 4.2 is a major release providing new video support and font management capabilities as well as other functionality so developers can efficiently create more modern and advanced user interfaces with less risk. VAPS XT 4.2 offers:

  • Improvements in the areas of text handling and high quality font rendering for HD displays and embedded platforms.
  • Live video support with flexible configuration of a variety of different video sources, together with replication and scaling having low resource impact, alpha blending and chroma key support.
  • Improved Editor features to streamline editing processes and improve usability.
  • ARINC 661 support including Supplement 6 GestureArea and TouchArea widgets.

"We are very proud of these new releases because they bring our suite of products to the next level. We have added new features to VAPS XT to solidify its position as the preferred choice of developers looking to create modern, real-time, interactive graphical HMI displays," said Paul Jennings, Head of Embedded Graphics Operations at Presagis.

ARINC 661 Tools

In addition, Presagis continues to advance its product offer for the ARINC 661 development market with the release of new versions of its UA Accelerator and UA Emulator products; these products are an integral part of Presagis' ARINC 661 Development Suite providing a complete ARINC 661 systems development environment for UA and CDS development. "Providing a complete and integrated ARINC 661 development suite for cost-effective and risk-free development of CDS and UA applications has always been our goal. Release 3.0 of UA Accelerator in conjunction with VAPS XT 661 positions us as the leading provider of ARINC 661 development tools for all phases of development of avionics systems," said Matt Jackson, Technical Product Manager of Embedded Graphics at Presagis.

About Presagis

Presagis is a global leader providing commercial modeling, simulation and user interface development solutions to the aerospace, defense and security, and critical infrastructure markets. Presagis combines an open simulation development framework with expert professional services to help customers streamline development workflows, reduce project risks, and deliver game-quality immersive simulations. Presagis is also at the forefront of avionics software design for certifiable cockpit displays. The company serves hundreds of customers worldwide, including many of the world's most respected organizations such as Boeing, Lockheed Martin, Airbus, BAE Systems, and CAE. For more information, visit www.presagis.com.

For more information contact:

Carlos Carpio
Presagis
Marketing Manager, Embedded Graphics
carlos.carpio@presagis.com 
514.341.3874 ext. 4374




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Presagis via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Oboya signs a cooperation agreement with Gaia regarding biomaterials13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry. Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide. The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are bi

Oboya tecknar ett samarbetsavtal med Gaia avseende biomaterial13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") har tecknat ett viktigt och långsiktigt samarbetsavtal avseende miljövänligt biomaterial med Gaia Biomaterials AB ("Gaia") i Helsingborg, Sverige. Avtalet innebär att Oboya använder Gaias biomaterial för tillverkning och utveckling av miljövänliga odlingsprodukter till odlingsindustrin. Oboya har under de senaste åren arbetat aktivt med innovation, miljö- och hållbarhetsfrågor och vårt mål är att främja miljö och hållbarhet inom odlingsindustrin genom att erbjuda miljövänliga odlingsprodukter till våra kunder. Oboya anser att användningen av biomaterial kommer att vara viktigt för framgång i omställningen till en fossilfri odlingsindustri världen över. Samarbetsavtalet innebär att Oboya använder Gaias biomaterial i sin produktion och att vi genom Gaias kompetens kan utveckla nya miljövänliga odlingsprodukter. Gaias biomaterial är biologiskt nedbrytbart, komposterbart samt ger upp till 80 % lägre koldioxidutsläpp vid förbränning jämfört

Stillfront: Simutronics reclaims publishing services10.12.2018 14:11Pressmeddelande

PRESS RELEASE December 10, 2018 Simutronics reclaims the publishing services for SIEGE: Titan Wars globally except China Simutronics Corp, a studio within Stillfront Group AB, has ended a co-publishing agreement regarding the mobile game SIEGE: Titan Wars with New York based publishing partner Tilting Point. According to a new agreement, Tilting Point will continue to provide publishing services and market the game in China but Simutronics will run the publishing services and marketing globally from the Group going forward. Simutronics is a leading developer of online roleplaying and mobile games such as DragonRealms, GemStone IV and Lara Croft Relic Run, the latter with more than 23 million downloads. Tilting Point is a new-generation games partner that provides top development studios with expert resources, services, and operational support to optimize high quality live games for success. "I am very pleased to continue the partnership with Tilting Point for the Chinese market as this

Stillfront: Simutronics återtar förläggartjänster10.12.2018 14:11Pressmeddelande

PRESSMEDDELANDE 2018-12-10 Simutronics återtar förläggartjänster för SIEGE: Titan Wars globalt med undantag för Kina Simutronics, en studio inom Stillfront Group, har avslutat ett medförläggaravtal avseende mobilspelet SIEGE: Titan Wars med den New York-baserade förläggarpartnern Tilting Point. Enligt ett nytt avtal kommer Tilting Point fortsatt att tillhandahålla förläggartjänster och marknadsföring av spelet i Kina men på global nivå kommer Simutronics att ansvara för förläggartjänster och marknadsföring av spelet från gruppen. Simutronics är en ledande utvecklare av rollspel och mobila spel som till exempel DragonRealms, GemStone IV och Lara Croft Relic Run, den sistnämnda med mer än 23 miljoner nedladdningar. Tilting Point är den nya generationens spelbolagspartner som förser ledande utvecklingsstudios med expertis, tjänster och operationell support för att optimera högkvalitativa livespel framgångsrikt. "Jag är mycket nöjd över det fortsatta partnerskapet med Tilting Point för den

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum